MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in May 2025.
The company's President and CEO, Kent Hawryluk, will present at the Citizens Life Sciences Conference on May 7, 2025 (3:00-3:25 p.m. ET) and the RBC 2025 Global Healthcare Conference on May 21, 2025 (3:35-4:00 p.m. ET). Both events will be held in New York and will feature fireside chats along with one-on-one meetings.
Investors can access live webcasts of both presentations through the company's website at investors.mbxbio.com/news-events/events. Replay recordings will be available approximately two hours after each event and remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MBX gained 13.09%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
The Citizens Life Sciences Conference
Date: Wednesday, May 7, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:00 p.m. – 3:25 p.m. ET
Location: New York, NY
The RBC 2025 Global Healthcare Conference
Date: Wednesday, May 21, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:35 p.m. – 4:00 p.m. ET
Location: New York, NY
The live webcast for each presentation can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND submission anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When and where will MBX Biosciences present at the Citizens Life Sciences Conference in May 2025?
How can investors access MBX Biosciences' May 2025 conference presentations?
What type of therapies is MBX Biosciences developing?
What is the schedule for MBX Biosciences' presentation at the RBC 2025 Global Healthcare Conference?
